Evidence map›Paper›PMID 41258136›Full record

ArticleBMC research notes2025

The influence of dopamine receptor SNPs on substance use disorder in a Jordanian cohort.

Ola Al-Sanabra, Laith Al-Eitan, Maryam Alasmar

Abstract read
In one paragraph

Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ola Al-SanabraDepartment of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Balqa Applied University, Al-Salt, 19117, Jordan. Ola.sanabra@bau.edu.jo.
Laith Al-EitanDepartment of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid, 22110, Jordan.
Maryam AlasmarDepartment of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid, 22110, Jordan.

Funding

The Scientific Research Support Fund (SRSF) at the Jordanian Ministry of Higher Education MPH/1/43/2017
6 · The paper itself

Abstract

objectiveGenetic factors are known to contribute to the development and progression of substance use disorder (SUD). Genes associated with dopamine-mediated reward pathways play a critical role in SUD. This study aimed to investigate the association of specific single nucleotide polymorphisms (SNPs) within the DRD1, DRD2, DRD3, DRD4, and DRD5 genes with SUD in a population of Jordanian males.

resultsA significant association was observed between the rs686 SNP and SUD, with the GG genotype showing a statistically significant association with SUD onset. The rs6280 (T > C) SNP in the DRD3 gene was significantly associated with SUD, as evidenced by both genotypic and allelic frequency analyses. Furthermore, the CG haplotype (rs4532, rs686) of DRD1 and the ACG haplotype (rs936461, rs936460, rs936465) of DRD4 were significantly associated with SUD onset, suggesting their potential roles as genetic risk factors. Multinomial logistic regression analysis identified smoking and marital status as factors significantly associated with the studied genotypes, further increasing the risk of SUD.

Indexed as

Genetic Predisposition to DiseasePolymorphism, Single NucleotideReceptors, DopamineSubstance-Related DisordersAdultCohort StudiesGene FrequencyGenotypeHaplotypesHumansJordanMaleMiddle AgedReceptors, Dopamine D1Receptors, Dopamine D2Receptors, Dopamine D3DRD1 protein, humanDRD2 protein, humanDRD3 protein, humanDRD4 protein, humanReceptors, DopamineReceptors, Dopamine D1Receptors, Dopamine D2Receptors, Dopamine D3Receptors, Dopamine D4AddictionArabDopamineDRDSNP

Identifiers

PMID41258136
PMCPMC12628939

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.